Recombinant T cell receptors that bind to NY-ESO-1 and / or LAGE-1A cancer antigens.

Recombinant T cell receptors targeting NY-ESO-1 and LAGE-1a antigens in an HLA-restricted manner address the limited availability of immunoreagents by enhancing immune response and inhibiting cancer growth through genetically modified T cells.

JP7893817B2Inactive Publication Date: 2026-07-22T CURE BIOSCIENCE INC
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-06-18
Publication Date
2026-07-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a limited availability of immunoreagents that effectively target the NY-ESO-1 and LAGE-1a cancer antigens, which are shared in an HLA-restricted manner, necessitating the development of novel compositions and methods for cancer treatment.

Method used

The development of recombinant T cell receptors that bind specifically to the NY-ESO-1 and/or LAGE-1a antigens in an HLA-restricted manner, comprising specific α and β chains with defined complementarity-determining regions (CDRs) for antigen recognition and binding, which can be used to generate genetically modified T cells for cancer therapy.

Benefits of technology

The recombinant T cell receptors enhance the immune response against cancer cells expressing NY-ESO-1 and/or LAGE-1a antigens, providing a targeted approach to inhibit cancer growth and treat or prevent cancer in subjects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007893817000003
    Figure 0007893817000003
  • Figure 0007893817000004
    Figure 0007893817000004
  • Figure 0007893817000005
    Figure 0007893817000005
Patent Text Reader

Abstract

The present invention relates to recombinant T cell receptors that specifically bind, in an MHC-restricted manner, to specific epitopes present in the shared cancer-testis antigen known as NY-ESO-1 and / or to specific epitopes present in the closely related antigen LAGE-1. The present invention provides T cell receptor-related polypeptides, fragments and functional variants thereof, as well as nucleic acids encoding the T cell receptor polypeptides of the invention, recombinant expression vectors and genetically modified cells (e.g., T cells) that express the T cell receptors, and their use in methods for diagnosing, treating, or preventing cancer in a subject.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • TCR (T Cell Receptor) for identifying NY-ESO (New York-Esophageal Squamous Cell Carcinomas)-1 antigen short peptide

    CN106632658A

  • NY-ESO-1-targeting T cell receptor and uses thereof

    CN108456247A

  • Cells transformed with nucleic acid encoding ny-ESO t cell receptors

    WO2008037943A1